Get the Stockscreener App
17.35
1.88%
0.32
After Hours:
17.50
0.15
+0.86%
Immunovant Inc stock is traded at $17.35, with a volume of 1.01M.
It is up +1.88% in the last 24 hours and up +7.36% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
See More
Previous Close:
$17.03
Open:
$17.04
24h Volume:
1.01M
Relative Volume:
0.67
Market Cap:
$3.02B
Revenue:
-
Net Income/Loss:
$-382.71M
P/E Ratio:
-6.6221
EPS:
-2.62
Net Cash Flow:
$-325.64M
1W Performance:
+4.83%
1M Performance:
+7.36%
6M Performance:
+18.19%
1Y Performance:
-42.93%
1-Day Range:
$16.82
$17.68
1-Week Range:
$15.95
$17.84
52-Week Range:
$12.72
$32.10
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
17.35 | 2.97B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Neutral |
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Key resistance and support levels for Immunovant Inc.July 2025 Rallies & Stepwise Trade Signal Implementation - newser.com
Will Immunovant Inc. stock outperform value stocksGold Moves & Safe Capital Investment Plans - newser.com
Why Immunovant Inc. stock is popular among millennialsJuly 2025 PreEarnings & Community Shared Stock Ideas - newser.com
Trend analysis for Immunovant Inc. this weekQuarterly Earnings Report & Risk Managed Investment Strategies - newser.com
Statistical indicators supporting Immunovant Inc.’s strengthJuly 2025 Movers & Expert Approved Momentum Ideas - newser.com
Visualizing Immunovant Inc. stock with heatmapsJuly 2025 Rallies & Stock Timing and Entry Methods - newser.com
How analysts rate Immunovant Inc. stock todayProduct Launch & Daily Entry Point Alerts - newser.com
Analyzing drawdowns of Immunovant Inc. with statistical toolsPortfolio Growth Summary & Stock Timing and Entry Methods - newser.com
Reversal indicators forming on Immunovant Inc. stockJuly 2025 Action & High Accuracy Swing Entry Alerts - newser.com
How hedge fund analytics apply to Immunovant Inc. stockDollar Strength & Short-Term Trading Alerts - newser.com
Immunovant (NASDAQ:IMVT) Insider Michael Geffner Sells 1,272 Shares - MarketBeat
Immunovant (NASDAQ:IMVT) Shares Up 7.2%Here's What Happened - MarketBeat
Immunovant’s chief technology officer sells $25,835 in stock By Investing.com - Investing.com Australia
Will breakout in Immunovant Inc. lead to full recovery2025 Technical Patterns & AI Driven Price Predictions - newser.com
Immunovant Inc. stock momentum explainedMarket Weekly Review & Daily Growth Stock Investment Tips - newser.com
Smart tools for monitoring Immunovant Inc.’s price action2025 Earnings Impact & Weekly Top Gainers Trade List - newser.com
JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37 - MSN
Published on: 2025-10-09 06:28:21 - newser.com
Using Ichimoku Cloud for Immunovant Inc. technicalsMarket Activity Summary & Real-Time Volume Analysis Alerts - newser.com
Is Immunovant Inc. forming a bottoming baseJuly 2025 Decliners & Community Trade Idea Sharing Platform - newser.com
Why Immunovant Inc. stock remains undervalued2025 Bull vs Bear & Stock Market Timing Techniques - newser.com
Platinum Investment Management Ltd. Grows Position in Immunovant, Inc. $IMVT - MarketBeat
Where is Immunovant (IMVT) Heading According to Analysts? - MSN
Immunovant (NASDAQ:IMVT) Given New $33.00 Price Target at JPMorgan Chase & Co. - MarketBeat
12 Best Strong Buy Stocks to Invest in According to Wall Street - Insider Monkey
Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue? - MSN
Is Asahi India Glass Limited One of the Top Picks for Growth Investors in YEARPrice Action Analysis & Free Phenomenal Trading Returns - earlytimes.in
What analysts say about Immunovant Inc stockFinancial Sector Performance & Free Proven Portfolio Growth Strategies - earlytimes.in
Banque Pictet & Cie SA Has $2.02 Million Stock Holdings in Immunovant, Inc. $IMVT - MarketBeat
Insider Sale: President & Immunovant CEO of $ROIV Sells 683,818 Shares - Quiver Quantitative
Immunovant, Inc. (NASDAQ:IMVT) Receives $33.60 Consensus PT from Analysts - MarketBeat
Aug Spikes: Is Immunovant Inc. a play on infrastructure spendingEarnings Recap Summary & Precise Buy Zone Tips - خودرو بانک
FOMO Trade: What are Immunovant Incs earnings expectations2025 Bull vs Bear & Fast Gaining Stock Strategy Reports - khodrobank.com
Gap Down: Should value investors consider Immunovant IncJuly 2025 Highlights & Safe Entry Point Identification - خودرو بانک
Live market analysis of Immunovant Inc.2025 Market Trends & Community Supported Trade Ideas - newser.com
Published on: 2025-09-19 07:03:28 - khodrobank.com
Trading Recap: Why is WANG LEE GROUP Inc stock going down2025 Fundamental Recap & Accurate Technical Buy Alerts - khodrobank.com
Sentiment Watch: What are analysts price targets for Immunovant IncJuly 2025 Gainers & Free Expert Approved Momentum Trade Ideas - khodrobank.com
Highs Report: How is Hoth Therapeutics Inc. managing supply chain issues2025 Market Trends & Daily Volume Surge Signals - khodrobank.com
IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA - GlobeNewswire
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunovant Inc Stock (IMVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Stout Jay S | Chief Technology Officer |
Oct 08 '25 |
Sale |
16.30 |
1,585 |
25,836 |
203,334 |
| Stout Jay S | Chief Technology Officer |
Jul 23 '25 |
Sale |
18.15 |
2,805 |
50,911 |
204,919 |
| Geffner Michael | Chief Medical Officer |
Jul 23 '25 |
Sale |
18.15 |
2,385 |
43,288 |
221,825 |
| Geffner Michael | Chief Medical Officer |
Jul 09 '25 |
Sale |
17.24 |
1,160 |
19,998 |
224,210 |
| Stout Jay S | Chief Technology Officer |
Jul 09 '25 |
Sale |
17.24 |
1,519 |
26,188 |
207,724 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):